Skip to content

Weekday Japan business intelligence for finance professionals.

Join the list
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company2 articles
Companies

Takeda Pharmaceutical Company Limited

Latest Tokyo Brief coverage on Takeda Pharmaceutical Company Limited, tracking filings, financial news, and market signals from Japan.

Code
4502
Exchange
TSE
Coverage
2 articles

Latest coverage

TSE:4502

  1. Takeda's ORZEYFUL Wins FDA Approval as First Drug to Treat Narcolepsy Type 1's Root Cause

    The FDA cleared Takeda's oral drug oveporexton to restore the orexin signaling missing in narcolepsy type 1, not just mask its symptoms, but a scheduling review by the US Drug Enforcement Administration still stands between approval and the first sale.

  2. Takeda's Yen Boost Masks a Flat Underlying Quarter

    A weaker yen pushed Takeda's quarterly revenue up 10.2%, but at constant currency sales actually fell 0.5% and net profit dropped 23.5%, more than double the decline shown in headline yen figures, even as full-year targets and the dividend forecast held steady.